News

NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.

NanoMedSyn has signed a research agreement with the French National Research Agency within the framework of the "Plan France Relance...

NanoMedSyn has been distinguished for its Growth Path by Bpifrance and joins the "Excellence" community.

NanoMedSyn has signed a 3-year Innovation Contract with the Occitanie Region for a "Research and Development of New Targeted Drugs"...

Dr. Marcel Garcia, co-founder and Scientific Director, is appointed President and Scientific Director of NanoMedSyn by the General Assembly. This...

This article demonstrates the involvement of acid phosphatases in the higher efficacy of AMFA-labelled enzyme therapy. J Cell Mol Med....

Shire and NanomedSyn enter into research agreement for potential lysosomal storage disorder treatment. This collaboration was stopped in September 2019....

NanoMedSyn  develops an efficient  treatment for refractory Pompe disease published by Journal of Controlled Release. J Control Release 2017, 269:15-23.

First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002/anie.201607824R2  

Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe's disease....

Lire l'article complet

Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours...

http://www.rare2015.com/index.php      

  Information reliée par l'Académie des sciences

 Published by ECOMNEWS on September 1st, 2015   Publihed by BIOTECHFINANCES on September 4th, 2015   Published by Heraultjuridique.com on...

Review in Languedoc-Roussillon Magazine, L’accent du Sud, N°38, p9” on Medical Research: “Nanoparticles to fight cancer”.

Publié dans Montpellier Agglo Novembre 2013